- Home
- INVA
INVA
Innoviva Inc.
as 06-26-2025 4:00pm EST
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.4B | IPO Year: | 2004 |
| Target Price: | $55.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.01 - $22.00 | Next Earning Date: | 07-30-2025 |
| Revenue: | $369,844,000 | Revenue Growth: | 18.70% |
| Revenue Growth (this year): | 3.75% | Revenue Growth (next year): | 12.62% |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
MT Newswires
16 days ago
Innoviva Says FDA Grants Priority Review to Zoliflodacin NDA for Treating Gonorrhea; Shares Up Pre-Bell
Business Wire
16 days ago
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Argus Research
18 days ago
INVA: Raising target price to $23.00
MT Newswires
18 days ago
Innoviva Says FDA Accepts New Drug Application for Zoliflodacin
Business Wire
18 days ago
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Business Wire
25 days ago
Innoviva to Participate in Upcoming Investor Conferences
Argus Research
a month ago
INVA: Raising target price to $20.00
Business Wire
a month ago
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.